Oric Pharmaceuticals, Inc. (ORIC)
12.62
-0.24
(-1.87%)
USD |
NASDAQ |
Sep 08, 16:00
12.50
-0.12
(-0.95%)
Pre-Market: 08:23
Oric Pharmaceuticals Enterprise Value : 1.046B for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 1.046B |
| September 04, 2026 | 1.071B |
| September 03, 2026 | 1.059B |
| September 02, 2026 | 1.099B |
| September 01, 2026 | 1.074B |
| August 31, 2026 | 1.085B |
| August 28, 2026 | 1.111B |
| August 27, 2026 | 1.163B |
| August 26, 2026 | 1.180B |
| August 25, 2026 | 1.172B |
| August 24, 2026 | 1.134B |
| August 21, 2026 | 1.210B |
| August 20, 2026 | 1.177B |
| August 19, 2026 | 1.257B |
| August 18, 2026 | 1.181B |
| August 17, 2026 | 1.125B |
| August 14, 2026 | 1.176B |
| August 13, 2026 | 1.160B |
| August 12, 2026 | 1.164B |
| August 11, 2026 | 1.161B |
| August 10, 2026 | 1.150B |
| August 07, 2026 | 1.138B |
| August 06, 2026 | 1.079B |
| August 05, 2026 | 1.079B |
| August 04, 2026 | 1.135B |
| Date | Value |
|---|---|
| August 03, 2026 | 837.11M |
| July 31, 2026 | 885.82M |
| July 30, 2026 | 944.89M |
| July 29, 2026 | 907.58M |
| July 28, 2026 | 972.87M |
| July 27, 2026 | 984.27M |
| July 24, 2026 | 992.56M |
| July 23, 2026 | 867.16M |
| July 22, 2026 | 852.66M |
| July 21, 2026 | 860.95M |
| July 20, 2026 | 818.46M |
| July 17, 2026 | 850.58M |
| July 16, 2026 | 850.58M |
| July 15, 2026 | 893.07M |
| July 14, 2026 | 831.93M |
| July 13, 2026 | 822.60M |
| July 10, 2026 | 863.02M |
| July 09, 2026 | 872.35M |
| July 08, 2026 | 868.20M |
| July 07, 2026 | 866.13M |
| July 06, 2026 | 869.24M |
| July 02, 2026 | 944.89M |
| July 01, 2026 | 867.16M |
| June 30, 2026 | 860.95M |
| June 29, 2026 | 772.27M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.49M |
| Total Expenses (Quarterly) | 41.49M |
| EPS Diluted (Quarterly) | -0.3841 |
| Earnings Yield | -10.70% |
| Normalized Earnings Yield | -10.70 |